Cargando…

Efficacy and Safety of iGlarLixi, Fixed-Ratio Combination of Insulin Glargine and Lixisenatide, Compared with Basal-Bolus Regimen in Patients with Type 2 Diabetes: Propensity Score Matched Analysis

INTRODUCTION: Basal-bolus (BB) regimens are generally used to intensify basal insulin therapy in patients with type 2 diabetes (T2D) not meeting glycemic targets. However, drawbacks include multiple injection burden and risk of weight gain and hypoglycemia. A once-daily titratable fixed-ratio combin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tabák, Ádám G., Anderson, John, Aschner, Pablo, Liu, Minzhi, Saremi, Aramesh, Stella, Peter, Tinahones, Francisco J., Wysham, Carol, Meier, Juris J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6965545/ https://www.ncbi.nlm.nih.gov/pubmed/31848983 http://dx.doi.org/10.1007/s13300-019-00735-7

Ejemplares similares

Propensity‐score‐matched comparative analyses of simultaneously administered fixed‐ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes
por: Rosenstock, Julio, et al.
Publicado: (2018)

Achievement of glycaemic control is associated with improvements in lipid profile with iGlarLixi versus iGlar: A post hoc analysis of the LixiLan‐L trial
por: Giorgino, Francesco, et al.
Publicado: (2019)

iGlarLixi: A New Once-Daily Fixed-Ratio Combination of Basal Insulin Glargine and Lixisenatide for the Management of Type 2 Diabetes
por: Hinnen, Debbie, et al.
Publicado: (2018)

iGlarLixi effectively reduces residual hyperglycaemia in patients with type 2 diabetes on basal insulin: A post hoc analysis from the LixiLan‐L study
por: Morea, Nicola, et al.
Publicado: (2020)

Bedtime-to-Morning Glucose Difference and iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of LixiLan-L
por: Zisman, Ariel, et al.
Publicado: (2018)

Modeling the Effect of Subcutaneous Lixisenatide on Glucoregulatory Endocrine Secretions and Gastric Emptying in Type 2 Diabetes to Simulate the Effect of iGlarLixi Administration Timing on Blood Sugar Profiles
por: Gautier, Thibault, et al.
Publicado: (2021)

Fixed‐ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improves ß‐cell function in people with type 2 diabetes
por: Ferrannini, Ele, et al.
Publicado: (2022)

More patients reach glycaemic control with a fixed‐ratio combination of insulin glargine and lixisenatide (iGlarLixi) than with basal insulin at 12 weeks of treatment: A post hoc time‐to‐control analysis of LixiLan‐O and LixiLan‐L
por: Frias, Juan, et al.
Publicado: (2018)

Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan‐O trial testing a titratable fixed‐ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponents
por: Davies, Melanie J., et al.
Publicado: (2017)

Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed‐ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan‐L trial
por: Wysham, Carol, et al.
Publicado: (2017)

Safety and Efficacy of Insulin Degludec/Liraglutide (IDegLira) and Insulin Glargine U100/Lixisenatide (iGlarLixi), Two Novel Co-Formulations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist, in Patients With Diabetes Not Adequately Controlled on Oral Antidiabetic Medications
por: Wysham, Carol H., et al.
Publicado: (2018)

Impact of disease duration and β‐cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on glucagon‐like peptide‐1 receptor agonist therapy: Exploratory analyses from the LixiLan‐G trial
por: Del Prato, Stefano, et al.
Publicado: (2020)

Effectiveness and Safety of iGlarLixi (Insulin Glargine 100 U/mL Plus Lixisenatide) in Type 2 Diabetes According to the Timing of Daily Administration: Data from the REALI Pooled Analysis
por: Haluzík, Martin, et al.
Publicado: (2023)

Initiation of iGlarLixi Versus Basal-Bolus Insulin in Adults With Type 2 Diabetes Advancing From Basal Insulin Therapy: The SoliComplex Real-World Study
por: Pantalone, Kevin M., et al.
Publicado: (2023)

Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study
por: Blonde, Lawrence, et al.
Publicado: (2021)

Translating iGlarLixi Evidence for the Management of Frequent Clinical Scenarios in Type 2 Diabetes
por: Skolnik, Neil, et al.
Publicado: (2021)

Concomitant iGlarLixi and Sodium-Glucose Co-transporter-2 Inhibitor Therapy in Adults with Type 2 Diabetes: LixiLan-G Trial and Real-World Evidence Results
por: Guja, Cristian, et al.
Publicado: (2021)

Effect of a single dose of insulin glargine/lixisenatide fixed ratio combination (iGlarLixi) on postprandial glucodynamic response in Japanese patients with type 2 diabetes mellitus: A phase I randomized trial
por: Inoue, Megumi, et al.
Publicado: (2019)

Real-world evidence on the use of a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) in people with suboptimally controlled type 2 diabetes in Romania: a prospective cohort study (STAR.Ro)
por: Bala, Cornelia, et al.
Publicado: (2022)

Effectiveness of IGlarLixi, a Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide, in People with Type 2 Diabetes
por: Kis, János Tibor, et al.
Publicado: (2021)

iGlarLixi Reduces Glycated Hemoglobin to a Greater Extent Than Basal Insulin Regardless of Levels at Screening: Post Hoc Analysis of LixiLan-L
por: Niemoeller, Elisabeth, et al.
Publicado: (2017)

Cost-Effectiveness of iGlarLixi in People with Type 2 Diabetes Mellitus Suboptimally Controlled on Basal Insulin Plus Metformin in the UK
por: McCrimmon, Rory J., et al.
Publicado: (2021)

Pharmacokinetics and Safety of iGlarLixi in Healthy Chinese Participants: Results of a Phase 1 Randomized Study
por: Xie, Panpan, et al.
Publicado: (2023)

iGlarLixi reduces residual hyperglycemia in Japanese patients with type 2 diabetes uncontrolled on basal insulin: A post‐hoc analysis of the LixiLan JP‐L trial
por: Yabe, Daisuke, et al.
Publicado: (2021)

Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in People with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the US
por: Shao, Hui, et al.
Publicado: (2022)

Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in Patients with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the UK
por: McCrimmon, Rory J., et al.
Publicado: (2022)

Comparing a daily versus weekly titration algorithm in people with type 2 diabetes switching from basal insulin to iGlarLixi in the LixiLan ONE CAN randomized trial
por: Hramiak, Irene, et al.
Publicado: (2022)

Treating Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in the Czech Republic: Cost-Effectiveness of IDegLira Versus iGlarLixi
por: Pöhlmann, Johannes, et al.
Publicado: (2019)

Efficacy and safety of iGlarLixi versus IDegAsp: Results of a systematic literature review and indirect treatment comparison
por: Home, Philip D., et al.
Publicado: (2021)

Findings for iGlarLixi versus BIAsp 30 confirmed in groups of people with type 2 diabetes with different biomedical characteristics
por: Home, Philip D., et al.
Publicado: (2022)

Clinical Benefits of Treating Patients with Type 2 Diabetes Mellitus with iGlarLixi: A Patient-Level Simulation Study
por: Chauhan, Ankita, et al.
Publicado: (2023)

iGlarLixi versus basal plus Rapid‐Acting insulin in adults with type 2 diabetes advancing from basal insulin therapy: The SoliSimplify Real‐World study
por: McCrimmon, Rory J., et al.
Publicado: (2022)

Use of iGlarLixi for Management of Type 2 Diabetes in Japanese Clinical Practice: SPARTA Japan, a Retrospective Observational Study
por: Matsuhisa, Munehide, et al.
Publicado: (2022)

Budget Impact Analysis of Intensification with iGlarLixi Compared to Alternative Treatment Strategies Among Patients with Type 2 Diabetes Mellitus
por: Ken-Opurum, Jennifer, et al.
Publicado: (2023)

Improved patient‐reported outcomes with iGlarLixi versus premix BIAsp 30 in people with type 2 diabetes in the SoliMix trial
por: Polonsky, William H., et al.
Publicado: (2022)

The Wedding Bells Sound Really Good! iGlarLixi Fixed-Ratio Combination in the Treatment of Type 2 Diabetes: A Narrative Review
por: Kwiendacz, Hanna, et al.
Publicado: (2023)

Use of iGlarLixi for the Management of Type 2 Diabetes in Japanese Clinical Practice: Prior Treatment Subgroup Analysis of the SPARTA Japan Study
por: Miyoshi, Hideaki, et al.
Publicado: (2023)

Effectiveness and Safety of iGlarLixi in People with Type 2 Diabetes in Adriatic Region Countries: ENSURE-ADR, a Real-World Study
por: Đekić, Danijel, et al.
Publicado: (2023)

Treatment persistence and adherence in people with type 2 diabetes switching to iGlarLixi vs free-dose combinations of basal insulin and glucagon-like peptide 1 receptor agonist
por: Edelman, Steven, et al.
Publicado: (2022)

Improved glycaemic control and weight benefit with iGlarLixi versus insulin glargine 100 U/mL in Chinese people with type 2 diabetes advancing their therapy from basal insulin plus oral antihyperglycaemic drugs: Results from the LixiLan‐L‐CN randomized controlled trial
por: Yuan, Xiaoyong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bt8n9djkrgsb9klgr35l7jm3jo